NZ628796A - Pure erlotinib - Google Patents
Pure erlotinibInfo
- Publication number
- NZ628796A NZ628796A NZ628796A NZ62879611A NZ628796A NZ 628796 A NZ628796 A NZ 628796A NZ 628796 A NZ628796 A NZ 628796A NZ 62879611 A NZ62879611 A NZ 62879611A NZ 628796 A NZ628796 A NZ 628796A
- Authority
- NZ
- New Zealand
- Prior art keywords
- erlotinib hydrochloride
- hydrochloride form
- solvent
- disclosed
- erlotinib
- Prior art date
Links
- 239000005551 L01XE03 - Erlotinib Substances 0.000 title 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 title 1
- 229960001433 erlotinib Drugs 0.000 title 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical group [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 abstract 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 abstract 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 abstract 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 abstract 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 238000002425 crystallisation Methods 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 abstract 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 abstract 1
- 229960005073 erlotinib hydrochloride Drugs 0.000 abstract 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2112MU2010 | 2010-07-23 | ||
| NZ606042A NZ606042A (en) | 2010-07-23 | 2011-07-22 | Process for the preparation of erlotinib and salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ628796A true NZ628796A (en) | 2016-02-26 |
Family
ID=44514823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ628796A NZ628796A (en) | 2010-07-23 | 2011-07-22 | Pure erlotinib |
| NZ606042A NZ606042A (en) | 2010-07-23 | 2011-07-22 | Process for the preparation of erlotinib and salts thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ606042A NZ606042A (en) | 2010-07-23 | 2011-07-22 | Process for the preparation of erlotinib and salts thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8952022B2 (enExample) |
| EP (1) | EP2595629A1 (enExample) |
| JP (2) | JP5948597B2 (enExample) |
| CN (1) | CN103124557A (enExample) |
| AU (1) | AU2011298167B2 (enExample) |
| CA (1) | CA2806273A1 (enExample) |
| NZ (2) | NZ628796A (enExample) |
| WO (1) | WO2012028861A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012028861A1 (en) | 2010-07-23 | 2012-03-08 | Generics [Uk] Limited | Pure erlotinib |
| CN103420924B (zh) * | 2012-05-25 | 2016-08-31 | 浙江九洲药业股份有限公司 | 一种盐酸埃罗替尼晶型a的制备方法 |
| WO2014023027A1 (zh) * | 2012-08-10 | 2014-02-13 | 上海创诺医药集团有限公司 | 盐酸埃罗替尼多晶型物及其制备方法 |
| WO2014118112A1 (en) * | 2013-01-29 | 2014-08-07 | Synthon B.V. | Pharmaceutical composition comprising erlotinib hydrochloride |
| WO2014118737A1 (en) | 2013-01-31 | 2014-08-07 | Ranbaxy Laboratories Limited | Erlotinib salts |
| CN104072427B (zh) * | 2013-03-29 | 2019-05-28 | 江苏豪森药业集团有限公司 | 盐酸厄洛替尼晶型的制备方法 |
| WO2020165672A1 (en) | 2019-02-15 | 2020-08-20 | Shivalik Rasayan Limited | Process for preparation of highly pure fingolimod hydrochloride |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0817775B1 (en) * | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| RS49836B (sr) | 1999-03-31 | 2008-08-07 | Pfizer Products Inc., | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
| UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| US7148231B2 (en) | 2003-02-17 | 2006-12-12 | Hoffmann-La Roche Inc. | [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph |
| US7625911B2 (en) | 2005-01-12 | 2009-12-01 | Mai De Ltd. | Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion |
| WO2007060691A2 (en) * | 2005-11-23 | 2007-05-31 | Natco Pharma Limited | A novel process for the preparation of erlotinib |
| US8372856B2 (en) | 2006-10-27 | 2013-02-12 | Synthon Bv | Hydrates of erlotinib hydrochloride |
| EP2170844B1 (en) | 2007-02-21 | 2016-05-04 | Natco Pharma Limited | Novel polymorphs of erlotinib hydrochloride and method of preparation |
| KR101441930B1 (ko) | 2007-04-04 | 2014-09-19 | 시플라 리미티드 | 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법 |
| US20090012295A1 (en) | 2007-06-25 | 2009-01-08 | Ales Gavenda | Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib |
| WO2009007984A2 (en) * | 2007-07-11 | 2009-01-15 | Hetero Drugs Limited | An improved process for erlotinib hydrochloride |
| EP2218713A1 (en) | 2007-08-17 | 2010-08-18 | Hetero Drugs Limited | Erlotinib hydrochloride polymorph Form A substantially free of polymorph Form B |
| TW200927732A (en) * | 2007-08-23 | 2009-07-01 | Plus Chemicals S A | Crystalline forms of erlotinib HCl and formulations thereof |
| US20090124642A1 (en) * | 2007-08-23 | 2009-05-14 | Augusto Canavesi | Crystalline forms of Erlotinib HCI and formulations thereof |
| KR20110017907A (ko) * | 2008-07-07 | 2011-02-22 | 플러스 케미칼스, 에스.에이. | 엘로티닙 염기 및 엘로티닙 ｈｃｌ의 결정형 |
| WO2010040212A1 (en) | 2008-10-08 | 2010-04-15 | Apotex Pharmachem Inc. | Processes for the preparation of erlotinib hydrochloride |
| WO2012028861A1 (en) | 2010-07-23 | 2012-03-08 | Generics [Uk] Limited | Pure erlotinib |
-
2011
- 2011-07-22 WO PCT/GB2011/051394 patent/WO2012028861A1/en not_active Ceased
- 2011-07-22 AU AU2011298167A patent/AU2011298167B2/en not_active Ceased
- 2011-07-22 US US13/811,628 patent/US8952022B2/en active Active
- 2011-07-22 NZ NZ628796A patent/NZ628796A/en not_active IP Right Cessation
- 2011-07-22 EP EP11741276.7A patent/EP2595629A1/en not_active Withdrawn
- 2011-07-22 JP JP2013520221A patent/JP5948597B2/ja active Active
- 2011-07-22 CN CN2011800459093A patent/CN103124557A/zh active Pending
- 2011-07-22 CA CA 2806273 patent/CA2806273A1/en not_active Abandoned
- 2011-07-22 NZ NZ606042A patent/NZ606042A/en not_active IP Right Cessation
-
2015
- 2015-01-06 US US14/590,519 patent/US9340515B2/en active Active
-
2016
- 2016-05-06 JP JP2016093409A patent/JP6374436B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NZ606042A (en) | 2015-05-29 |
| US20150111847A1 (en) | 2015-04-23 |
| JP5948597B2 (ja) | 2016-07-06 |
| US20130210842A1 (en) | 2013-08-15 |
| WO2012028861A1 (en) | 2012-03-08 |
| US8952022B2 (en) | 2015-02-10 |
| US9340515B2 (en) | 2016-05-17 |
| AU2011298167A8 (en) | 2013-02-21 |
| JP2013531058A (ja) | 2013-08-01 |
| JP6374436B2 (ja) | 2018-08-15 |
| EP2595629A1 (en) | 2013-05-29 |
| JP2016196463A (ja) | 2016-11-24 |
| CA2806273A1 (en) | 2012-03-08 |
| AU2011298167A1 (en) | 2013-02-07 |
| CN103124557A (zh) | 2013-05-29 |
| AU2011298167B2 (en) | 2015-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ628796A (en) | Pure erlotinib | |
| JOP20210065A1 (ar) | عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة | |
| NZ739645A (en) | Form i of compound a, process for its preparation, and its use in the manufacture of a medicament for treating thyroid hormone resistance-associated diseases | |
| EP4245369A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| PH12013501727A1 (en) | Heteroaryl derivatives as alpha7 nachr modulators | |
| WO2011110876A8 (en) | Novel salts for the manufacture of pharmaceutical compositions | |
| UA97478C2 (ru) | Кристаллическая форма vi агомелатина, способ ее приготовления (варианты) и фармацевтическая композиция, которая ее содержит | |
| PH12015501226A1 (en) | Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same | |
| WO2013121235A3 (en) | Process for preparation of dronedarone by removal of hydroxyl group | |
| AU2012245971A8 (en) | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation | |
| WO2013093931A3 (en) | Novel prodrugs of phenolic drugs | |
| AU2014224456A8 (en) | Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same | |
| MY143557A (en) | Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it | |
| MX337721B (es) | Compuestos de heteroarilo como ligandos del receptor 5-ht4. | |
| MY151035A (en) | ? crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it | |
| WO2015042414A8 (en) | Multicyclic compounds and methods of using same | |
| WO2013140265A3 (en) | Fertility enhancing agent | |
| MD20120130A2 (en) | Delta crystalline form of the L-arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it | |
| WO2012115402A3 (en) | Crystalline form of docetaxel and process for preparation thereof | |
| MX2009008068A (es) | Compuesto macrolido en forma solida, proceso para su preparacion y composicion farmaceutica que lo contiene. | |
| SG194711A1 (en) | Processes for preparing inhibitors of the hepatitis c virus | |
| WO2014199244A3 (en) | Crystalline imatinib mesylate process | |
| CA2928305C (en) | A crystalline anhydrous form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof | |
| SA112330994B1 (ar) | عملية جديدة لتخليق إيفابردين وأملاح الإضافة الخاصة به مع حمض مقبول صيدلانياً | |
| WO2014155371A3 (en) | Crystalline lenalidomide process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 JUL 2018 BY SPRUSON + FERGUSON Effective date: 20160630 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUL 2019 BY RENEWALS TEAM Effective date: 20180614 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUL 2020 BY RENEWALS TEAM Effective date: 20190715 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUL 2021 BY RENEWALS TEAM Effective date: 20200715 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUL 2022 BY IPAN GMBH Effective date: 20210708 |
|
| LAPS | Patent lapsed |